Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Health risk assessment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,001 result(s) found for: Health risk assessment. Displaying page 1 of 51.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-005285-38 Sponsor Protocol Number: IM101-591 Start Date*: 2020-01-14
    Sponsor Name:The University of Leeds
    Full Title: Phase II proof of concept study of Abatacept (Orencia) in individuals who aRe Considered At risk of Developing Inflammatory Arthritis
    Medical condition: Inflammatory arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10003246 Arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-004135-89 Sponsor Protocol Number: D516FC00001 Start Date*: 2022-04-07
    Sponsor Name:AstraZeneca AB
    Full Title: Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Sta...
    Medical condition: Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029517 Non-small cell lung cancer stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005095-18 Sponsor Protocol Number: ICR-CTSU/2013/10041 Start Date*: 2014-09-19
    Sponsor Name:The Institute of Cancer Research
    Full Title: A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.
    Medical condition: Low risk non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-001699-20 Sponsor Protocol Number: 042011 Start Date*: 2012-05-18
    Sponsor Name:St. Anna Kinderkrebsforschung, GmbH
    Full Title: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS
    Medical condition: Langerhans cell histiocytosis
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002089-11 Sponsor Protocol Number: CMBG453B12301 Start Date*: 2020-06-23
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodyspla...
    Medical condition: adult subjects with intermediate, high or very high risk (per IPSS-R prognostic risk categories) myelodysplastic syndrome or with Chronic Myelomonocytic Leukemia - 2 (CMML-2)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) IT (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) FI (Prematurely Ended) LT (Completed) NL (Prematurely Ended) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000003-16 Sponsor Protocol Number: UPBEAT-TIF Start Date*: 2018-11-06
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: Prevention of Gestational Diabetes in Obese Pregnant Women; a Proof of Principle Study Targeting Early Pregnancy Intervention to Women at Risk
    Medical condition: Gestational diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004868 10018210 Gestational diabetes mellitus LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-001891-21 Sponsor Protocol Number: NC25608 Start Date*: 2012-02-21
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary H...
    Medical condition: Patients with stable CHD, CHD risk equivalents (including PAD, cerebrovascular disease, and T2D), or at elevated risk for CV mortality and morbidity on the basis of multiple risk factors for CVD by...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002828-85 Sponsor Protocol Number: RG_15-114 Start Date*: 2017-04-28
    Sponsor Name:University of Birmingham
    Full Title: Paediatric Hepatic International Tumour Trial
    Medical condition: Hepatoblastoma and Hepatocellular Carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062001 Hepatoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) DE (Ongoing) CZ (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) AT (Ongoing) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004287-26 Sponsor Protocol Number: 5F9009 Start Date*: 2021-05-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplas...
    Medical condition: Intermediate/high/very high risk myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) BE (Completed) IE (Prematurely Ended) NL (Completed) AT (Prematurely Ended) DK (Prematurely Ended) PT (Prematurely Ended) NO (Prematurely Ended) FI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004868-30 Sponsor Protocol Number: PNET5MB Start Date*: 2013-10-31
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (...
    Medical condition: Children with medulloblastoma. Medulloblastoma is a highly cellular malignant embryonal neoplasm.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) NO (Completed) CZ (Trial now transitioned) NL (Trial now transitioned) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003139-47 Sponsor Protocol Number: EFC15992 Start Date*: 2021-06-17
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smo...
    Medical condition: Smoldering Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) SE (Completed) NO (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) DE (Trial now transitioned) LT (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) IE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004250-17 Sponsor Protocol Number: RG_18-205,BN3010 Start Date*: 2019-10-11
    Sponsor Name:University of Birmingham
    Full Title: An International Prospective Trial on High-Risk Medulloblastoma in Patients Older than 3 Years
    Medical condition: Histologically proven high-risk medulloblastoma, with any of the currently defined histological subtypes. High-risk disease is defined as patients with sonic hedgehog (SHH) subgroup or non-SHH/non-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004024-37 Sponsor Protocol Number: A6181109 Start Date*: 2007-07-05
    Sponsor Name:Pfizer Inc. - 235 East 42nd Street - New York - 10017
    Full Title: SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT SUNITINIB VS. PLACEBO IN SUBJECTS WITH HIGH RISK RCC
    Medical condition: Adjuvant treatment of subjects with “high risk” Renal Cell Carcinoma (RCC) following nephrectomy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038408 Renal cell carcinomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) CZ (Completed) DE (Completed) GR (Completed) AT (Completed) IT (Completed) IE (Completed) SE (Completed) PL (Completed) SK (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004800-20 Sponsor Protocol Number: MK-3475-937 Start Date*: 2019-08-22
    Sponsor Name:Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete ...
    Medical condition: Adjuvant treatment of HCC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004479-11 Sponsor Protocol Number: CMBG453B12201 Start Date*: 2019-05-30
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodys...
    Medical condition: Adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) AT (Prematurely Ended) GR (Completed) HU (Completed) NO (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005255-87 Sponsor Protocol Number: 2014-13 Start Date*: 2016-05-04
    Sponsor Name:Assistance Publique Hôpitaux de MARSEILLE
    Full Title: Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study.
    Medical condition: Patients with intermediate-risk gastrointestinal stromal tumor presenting a high Genomic Grade Index
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022576-30 Sponsor Protocol Number: BA058-05-003 Start Date*: 2011-02-21
    Sponsor Name:Radius Health, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopau...
    Medical condition: Osteoporosis in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) LT (Completed) DK (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003014-13 Sponsor Protocol Number: 19SARC05 Start Date*: 2020-02-12
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized grade 1 or 2 Soft Tissue Sarcoma.
    Medical condition: Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004425-27 Sponsor Protocol Number: 5863 Start Date*: 2012-05-29
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: Study of Optimal Replacement of Thyroxine in the ElDerly (SORTED) SORTED 1 – a Randomised Controlled Trial (Pilot study) SORTED 2 – Qualitative Interviews SORTED 3 – Retrospective Cohort
    Medical condition: hypothyroidism (elderly individuals)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001488-60 Sponsor Protocol Number: WSG-AM11 Start Date*: 2020-07-09
    Sponsor Name:Westdeutsche Studiengruppe GmbH
    Full Title: A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus stand...
    Medical condition: HR+/HER2- early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 11:41:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA